{"disease":{"id":"follicular-b-cell-non-hodgkin-s-lymphoma","name":"follicular b cell non hodgkin s lymphoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01000753","title":"Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma","phase":"","overall_status":"COMPLETED","enrollment_count":174,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT04870853","title":"Cardiovascular Events Among Adults Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Standard of Care Chimeric Antigen Receptor T Cell Therapy","phase":"","overall_status":"UNKNOWN","enrollment_count":150,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT00719888","title":"Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":135,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":true},{"nct_id":"NCT02332980","title":"Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":65,"lead_sponsor_name":"Mayo Clinic","has_results":true},{"nct_id":"NCT00856388","title":"Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders","phase":"NA","overall_status":"COMPLETED","enrollment_count":62,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT02213913","title":"Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":55,"lead_sponsor_name":"University of Chicago","has_results":true},{"nct_id":"NCT03150329","title":"Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":52,"lead_sponsor_name":"City of Hope Medical Center","has_results":true},{"nct_id":"NCT02494700","title":"Ultra Low Dose Orbital Radiation Therapy in Treating Patients With Stage I-IV Indolent B-cell Lymphoma or Mantle Cell Lymphoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":50,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT00795769","title":"Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":true},{"nct_id":"NCT05627245","title":"Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":48,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05025800","title":"ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":47,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT01129193","title":"AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":44,"lead_sponsor_name":"Amir Mortazavi","has_results":false},{"nct_id":"NCT05169658","title":"Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":42,"lead_sponsor_name":"University of Washington","has_results":false},{"nct_id":"NCT06834373","title":"Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":41,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT05453396","title":"Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"University of Washington","has_results":false},{"nct_id":"NCT06536049","title":"Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":38,"lead_sponsor_name":"Yazeed Sawalha","has_results":false},{"nct_id":"NCT05672251","title":"Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT01588015","title":"Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT02568553","title":"Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":35,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07098364","title":"ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":33,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":false},{"nct_id":"NCT05784415","title":"Observational Study of People Living With HIV Treated With CD19-directed CAR T Cell","phase":"","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"AIDS Malignancy Consortium","has_results":false},{"nct_id":"NCT03198026","title":"Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":30,"lead_sponsor_name":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","has_results":false},{"nct_id":"NCT06784726","title":"Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":27,"lead_sponsor_name":"University of Washington","has_results":false},{"nct_id":"NCT05359211","title":"NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":27,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":false},{"nct_id":"NCT01897012","title":"Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02520791","title":"Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":21,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01044745","title":"Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":20,"lead_sponsor_name":"University of Nebraska","has_results":true},{"nct_id":"NCT05077527","title":"Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"AIDS Malignancy Consortium","has_results":false},{"nct_id":"NCT04205409","title":"Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":20,"lead_sponsor_name":"University of Washington","has_results":true},{"nct_id":"NCT05360238","title":"Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":20,"lead_sponsor_name":"Mustang Bio","has_results":false},{"nct_id":"NCT01805037","title":"Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":20,"lead_sponsor_name":"Northwestern University","has_results":true},{"nct_id":"NCT03583424","title":"Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":19,"lead_sponsor_name":"Ohio State University Comprehensive Cancer Center","has_results":true},{"nct_id":"NCT06209619","title":"CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":18,"lead_sponsor_name":"Nathan Denlinger","has_results":false},{"nct_id":"NCT03479268","title":"Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":18,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT03210662","title":"Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":17,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT03598998","title":"Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":13,"lead_sponsor_name":"City of Hope Medical Center","has_results":true},{"nct_id":"NCT04156828","title":"Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":12,"lead_sponsor_name":"University of Washington","has_results":false},{"nct_id":"NCT03035331","title":"Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":11,"lead_sponsor_name":"Mayo Clinic","has_results":true},{"nct_id":"NCT01381692","title":"Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":9,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04578600","title":"CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":8,"lead_sponsor_name":"Joseph Tuscano","has_results":false},{"nct_id":"NCT05645744","title":"Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.","phase":"","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"Mustang Bio","has_results":false},{"nct_id":"NCT04659044","title":"Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"Academic and Community Cancer Research United","has_results":true},{"nct_id":"NCT02950220","title":"Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":2,"lead_sponsor_name":"Kami Maddocks","has_results":false},{"nct_id":"NCT03579927","title":"CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma","phase":"PHASE1, PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04635683","title":"Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma","phase":"PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Yazeed Sawalha","has_results":false},{"nct_id":"NCT04995536","title":"CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL","phase":"PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"City of Hope Medical Center","has_results":false}],"total":46},"guidelines":[],"source":"Drug Landscape verified database"}